Decreased serum concentrations of sphingosine-1-phosphate in sepsis by unknown
RESEARCH Open Access
Decreased serum concentrations of
sphingosine-1-phosphate in sepsis
Martin Sebastian Winkler1*†, Axel Nierhaus2†, Maximilian Holzmann1, Eileen Mudersbach3, Antonia Bauer1,
Linda Robbe1, Corinne Zahrte2, Maria Geffken4, Sven Peine4, Edzard Schwedhelm3, Guenter Daum5,
Stefan Kluge2 and Christian Zoellner1
Abstract
Introduction: Sphingosine-1-phosphate (S1P) is a signaling lipid that regulates pathophysiological processes
involved in sepsis progression, including endothelial permeability, cytokine release, and vascular tone. The aim of
this study was to investigate whether serum-S1P concentrations are associated with disease severity in patients
with sepsis.
Methods: This single-center prospective-observational study includes 100 patients with systemic inflammatory
response syndrome (SIRS) plus infection (n = 40), severe sepsis (n = 30), or septic shock (n = 30) and 214 healthy
blood donors as controls. Serum-S1P was measured by mass spectrometry. Blood parameters, including C-reactive
protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), lactate, and white blood cells (WBCs), were determined by routine
assays. The Sequential Organ Failure Assessment (SOFA) score was generated and used to evaluate disease severity.
Results: Serum-S1P concentrations were lower in patients than in controls (P < 0.01), and the greatest difference was
between the control and the septic shock groups (P < 0.01). Serum-S1P levels were inversely correlated with disease
severity as determined by the SOFA score (P < 0.01) as well as with IL-6, PCT, CRP, creatinine, lactate, and fluid balance.
A receiver operating characteristic analysis for the presence or absence of septic shock revealed equally high sensitivity
and specificity for S1P compared with the SOFA score. In a multivariate logistic regression model calculated for
prediction of septic shock, S1P emerged as the strongest predictor (P < 0.001).
Conclusions: In patients with sepsis, serum-S1P levels are dramatically decreased and are inversely associated with
disease severity. Since S1P is a potent regulator of endothelial integrity, low S1P levels may contribute to capillary
leakage, impaired tissue perfusion, and organ failure in sepsis.
Introduction
Sepsis is a major clinical and health-care problem affecting
millions of people worldwide [1]. In the US, hospitaliza-
tions for sepsis doubled from 326,000 in 2000 to 727,000
in 2008 [2]. Despite considerable efforts to understand the
pathophysiology of sepsis and to find new treatments over
the last decades, mortality remains high. In 2008, in the
US, the mortality rate of patients with septicemia or sepsis
was 17 % whereas the mortality rate of other hospitaliza-
tions was only 2 % [2]. Immediate therapy of sepsis is of
great importance as patient survival depends on timely
antibiotic treatment [3], which should be considered
already in the pre-hospital setting [4].
Sepsis is an acute life-threatening condition of the host
to an underlying infection. With increasing severity, the
effectors of the immune response are damaging tissues
and organs [5]. Importantly, pro-inflammatory and anti-
inflammatory responses coexist in sepsis and invariably
cause severe organ dysfunction, septic shock, and im-
munosuppression [6].
Hallmarks for sepsis severity include endothelial bar-
rier disruption, uncontrolled cytokine secretion, and
hypotension, all of which are potentially regulated by
sphingosine-1-phosphate (S1P).
S1P is a bioactive sphingolipid that regulates many
physiological as well as pathophysiological processes in
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the vasculature and immune systems [7, 8]. S1P is present
at high concentrations in plasma where it is bound mainly
to albumin or high-density lipoprotein (HDL). It is pro-
duced by two sphingosine-kinases (SphK 1 and 2) and
degraded by dephosphorylation or cleavage. Most of its
effects are mediated by five specific G protein-coupled
receptors (S1PR1-5). S1PR1 is critical for endothelial
integrity as has been demonstrated by the lethality of
genetic S1PR1 deletion in mice, which die in utero
from hemorrhage [9]. Moreover, mice with greatly de-
creased plasma-S1P levels display increased vascular
leakage and impaired survival after inflammatory chal-
lenge [10]. In contrast, intravenous application of S1P to
mice and dogs attenuates barrier dysfunction in lungs fol-
lowing lung injury [11]. Anti-inflammatory properties of
S1P have been observed in a mouse H1N1-influenza virus
infection model, in which oral administration of S1PR1
agonists inhibits early pro-inflammatory cytokine produc-
tion and innate immune cell recruitment [12]. At last, a
role for S1P to maintain the vascular tone has been dem-
onstrated in various arterial beds [13]. Considering these
observations, we sought to investigate whether serum-S1P




From March until December 2014, 100 patients
(>18 years old) who were admitted to the intensive care
unit (ICU) of the University Medical Center Hamburg-
Eppendorf (Hamburg, Germany) with different stages of
sepsis were enrolled after informed consent had been
obtained from patients or their legal representatives.
The study protocol was approved by the ethical review
committee of the local medical chamber of Hamburg
(Aerztekammer Hamburg, reference number PV4550).
Inclusion criteria were a diagnosed infection or a clin-
ical syndrome pathognomonic for an infection. Patients
were categorized into three groups on the basis of the
criteria published by the American College of Chest
Physicians/Society of Critical Care Medicine [14]. Sys-
temic inflammatory response syndrome (SIRS) plus in-
fection/sepsis (group A) was defined as an infectious
disease with at least two SIRS criteria: temperature of
more than 38 °C or less than 36 °C, heart rate of more
than 90 beats per minute, respiratory rate of more than
20 per minute or partial pressure of arterial carbon diox-
ide (PaCO2) of less than 32 mm Hg, and white blood cell
(WBC) count of more than 12 × 109/l or less than 4 × 109/l.
Severe sepsis (group B) was defined as sepsis and the pres-
ence of the following organ failure: acute encephalopathy,
thrombocytopenia (reduction of at least 30 % in 24 hours
or platelets of not more than 100 × 109/l), hypoxia (partial
pressure arterial oxygen (PaO2) of not more than 4.3 kPa/
75 mm Hg with room air or PaO2/fraction of inspired oxy-
gen (FiO2) of not more than 33 kPa/250 mm Hg under
oxygen), renal dysfunction (urine output of not more than
0.5 ml/kg per hour in 2 hours despite sufficient fluids), re-
suscitation or increase of serum creatinine (of more than
2×) or both, metabolic acidosis (Base excess of not more
than −5 mmol/l or lactate of more than 1.5 mmol/l), or
hypotension/cardiovascular dysfunction (after fluid resus-
citation with at least 30 ml/kg of crystalloid). Septic shock
(group C) was defined as severe sepsis with hypotension
requiring vasopressor support or persistent hypotension
for more than 1 hour despite adequate fluid resuscitation.
The control cohort consisted of 214 volunteers donat-
ing blood at the Institute of Transfusion Medicine, Uni-
versity Medical Center Hamburg-Eppendorf (Hamburg,
Germany). All blood donations were performed in ac-
cordance with the latest (2010) guidelines of the German
Federal Medical Council (Bundesaerztekammer), which
specifically exclude blood donations from subjects with
severe health problems. In accordance with ethics regu-
lations, samples were anonymized; only age and gender
were reported. Blood was processed as described below
for patients.
Clinical evaluations and assays
For all patients with diagnosed sepsis, a Simplified Acute
Physiology Score (SAPS) II [15] and a Sequential Organ
Failure Assessment (SOFA) score were generated [16].
The SOFA score was calculated on admission as previously
described [16]. Within the first 24 hours after inclusion,
the fluid balance (calculated as fluid intake minus fluid
loss) was recorded and blood was drawn to measure S1P
and to determine clinical parameters, including WBC
counts, creatinine, lactate, C-reactive protein (CRP), pro-
calcitonin (PCT), and interleukin-6 (IL-6). All routine clin-
ical assays were performed at the Department of Clinical
Chemistry at the University Hospital Hamburg-Eppendorf.
Serum preparation and S1P measurements
Blood samples from controls and patients were proc-
essed the same way. After coagulation at 4 °C, samples
were cleared by centrifugation and serum immediately
frozen and stored at −80 °C until S1P was measured.
Serum-S1P measurements were performed by using a
previously described protocol with minor modifications
[17]. After the addition of internal standard (1 nmol/ml
C17-S1P; Avanti Polar Lipids, Alabaster, AL, USA),
serum was de-proteinated by the addition of acetonitrile
(final concentration of 70 %). Extracts were cleared by
centrifugation and subjected to reverse-phase chro-
matography on a Zorbax SB-C8 column (2.1 × 50 mm;
Agilent Technologies, Santa Clara, CA, USA) at a flow
rate of 0.35 ml/min. S1P was eluted by a binary gradient
(2.5 % methanol, 2.5 % acetonitrile, 0.1 % formic acid to
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30 % methanol, 30 % acetonitrile, 0.1 % formic acid; % =
volume %) and measured by a Varian MS 1200 mass
spectrometer by using multiple reaction mode in which
the M +H S1P parent ion (m/z = 380) is fragmented to
form a daughter ion at m/z = 264, which is then used for
quantitation. The internal standard (C17-S1P) with the
m/z 366-to-250 transition was used to correct for varia-
tions in sample preparation and instrument response. A
calibration curve (0.1-3 nmol/ml S1P) was generated to
calculate absolute S1P concentrations in samples.
Statistical analysis
The primary variable is the serum-S1P concentration in
nanomoles per liter. All variables were tested for normal
distribution and transformed if necessary as indicated in
the figures or tables. Differences between groups were
tested for significance by using either the non-parametric
Mann–Whitney U test for two groups or the Kruskal-
Wallis analysis of variance for more than two groups. Data
are presented as median with interquartile range or as
mean with standard error of the mean. Correlations were
calculated by using linear regression or the Spearman test.
Receiver operating characteristic (ROC) curves were gener-
ated, and areas under the curve (AUC) were calculated.
Odds ratios with 95 % confidence intervals (CIs) were
computed by using a multivariate logistic regression model
with septic shock as the dependent variable. For all tests, a
P value of less than 0.05 was considered significant. Statis-
tical analyses were performed by using SPSS (version 21;
IBM Corporation, Armonk, NY, USA) with guidance from
members of the Department of Medical Biometry and Epi-
demiology at the University Hospital Hamburg-Eppendorf.
Results and discussion
Patients with sepsis have lower serum-S1P concentrations
than controls
Serum-S1P concentrations were measured in 100 patients
with sepsis and 214 healthy controls by mass spectrometry
after de-proteinization of serum with acetonitrile. This
method determines the total S1P content in serum regard-
less of the nature of the S1P-binding protein. It should be
noted that, during coagulation, platelets release S1P and
so contribute to total serum-S1P levels [18]. The two
study groups did not differ regarding sex distribution; how-
ever, the control group was younger on average (Table 1).
Neither an age dependency nor a gender bias was detected
in controls (Fig. 1). Patients with sepsis had significantly
lower mean serum-S1P levels (580 ± 24 nmol/l) than
controls (1156 ± 17 nmol/l; Fig. 2). The patient cohort was
then divided into three groups (groups A-C) of increasing
disease severity. Consistent with this classification, ICU
stays were the longest for patients with septic shock (group
C), followed by patients with severe sepsis (group B) or
sepsis (group A). Also, the death rate in groups B and C
was about 10 times higher than in group A (Table 1). The
three patient groups did not differ in age or sex distri-
bution or in reasons for admission (medical or surgical;
Table 1). When serum-S1P levels between the three groups
were compared, group C presented with significantly lower
levels than group A or B (Fig. 2).
There is an association between serum-S1P concentrations
and the Sequential Organ Failure Assessment score
SOFA scores indicate disease severity in critically ill pa-
tients regardless of the underlying disease and therefore
are generally used to predict mortality in ICU patients
[16]. Linear regression analysis revealed a strong inverse
correlation between SOFA scores and serum-S1P levels
with a regression coefficient (r) of −0.45 (P < 0.01; Fig. 3a).
To demonstrate that serum-S1P is linked not only to
disease severity but also to mortality, patients were
classified into four groups with increasing SOFA
score. For each group, the mortality rate and average
serum-S1P concentrations were calculated. We also found
that mortality was inversely associated with serum-S1P
levels (Fig. 3b).
Table 1 Characteristics of study groups
Controls All patients Group A Group B Group C **Significance (P) –
Group A to CSIRS + Infection Severe sepsis Septic shock
Number 214 100 40 30 30 N/A
*Age, years 36 (27–51) 59 (51–70) 59 (46–67) 60 (53–72) 65 (56–74) n.s.
Men/Women, n (%) 129/85 (60/40) 58/42 (58/42) 22/18 (55/45) 20/10 (67/33) 16/14 (53/47) n.s.
Admission medical/surgical, n (%) N/A 56/44 (56/44) 20/20 (50/50) 20/10 (67/33) 16/14 (53/47) n.s.
*SAPS II, median (IQR) N/A 33 (24–42) 28 (17–35) 34 (30–41) 42 (30–47) <0.01
*Length of ICU stay, days N/A 7 (2–11) 2 (1–6) 8 (4–12) 11 (7–21) <0.01
Death on ICU, n (%) N/A 15 (15.0) 1 (2.5) 7 (23.3) 7 (23.3) <0.05
SIRS systemic inflammatory response syndrome, N/A not applicable, n.s. non-significant, SAPS II Simplified Acute Physiology Score II, IQR interquartile range, ICU
intensive care unit
*Data are presented as median and IQR
**Groups were compared by using analysis-of-variance Kruskal-Wallis test
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Serum-S1P concentrations predict septic shock with high
accuracy
Given the association found between the SOFA score
and serum-S1P, we also tested for correlations between
S1P and the common inflammatory markers such as IL-
6, PCT, and CRP as well as for creatinine, lactate, and
fluid balance, all of which are increased in sepsis. All pa-
rameters tested showed a statistically significant inverse
correlation to S1P with the strongest determined for
PCT, followed by IL-6, CRP, creatinine, lactate, and fluid
balance (Table 2). To compare the potential of various
parameters with S1P as to indicate septic shock within
patients with sepsis, an ROC analysis, including S1P, the
SOFA score, IL-6, CRP, PCT, and lactate, was performed.
Among all parameters tested, SOFA score and S1P
emerged as the most powerful indicators of septic shock,
with almost identical AUCs of 0.88 (95 % CI, 0.82-0.95)
for S1P and 0.87 (95 % CI 0.81-0.95) for SOFA score
(Fig. 4). The ROC curves for all other markers were
similar, with AUCs of between 0.66 and 0.74. To further
demonstrate the potential of SOFA score and S1P to
predict septic shock, a multivariate logistic regression
analysis for all parameters was performed. Multivariate
logistic regression showed S1P as the strongest predictor
(P < 0.001) followed by SOFA score (P <0.01) and all
other parameters (Table 3).
Discussion
The main findings of our study are that patients with sep-
sis, and particularly those with hypotensive septic shock,
have decreased serum S1P concentrations and that high
serum S1P levels might be able to rule out the risk of
having septic shock with a high probability. Serum-S1P
concentrations are associated with sepsis severity.
Our serum-S1P measurements in controls are in
agreement with two previous studies that reported aver-
age serum-S1P concentrations for healthy control groups
of 900 and 1400 nmol/l [19, 20]. In patients with sepsis,
serum-S1P is approximately 50 % lower than in controls
(Fig. 2). Moreover, serum-S1P concentrations were low-
est in the most severely affected patients (group C, sep-
tic shock; Fig. 2); and a multivariate regression analysis
with septic shock as the dependent variable showed that
a small decrease in serum-S1P concentration of only
1 nmol/l was associated with an increased risk of devel-
oping septic shock of 1.2 % (Table 3).
As blood samples from patients and controls were
handled and processed the same way and as we did not
observe an age dependency or gender bias for serum-
S1P concentrations, we conclude that the difference in
serum-S1P concentrations between patients and controls
was due to sepsis.
Sepsis is characterized by multiple pathophysio-
logical processes, including immunological stimula-
tion, systemic inflammation, and coagulopathy, which
vary in degree from patient to patient [21, 22]. There-
fore, one might expect that a complex score address-
ing diverse clinical parameters is required to assess
sepsis severity. For instance, the SOFA score that pre-
dicts progression and mortality of critically ill patients
with high accuracy consists of evaluations of six dif-
ferent organ systems: the respiratory, cardiovascular,
hepatic, renal, neurological, and coagulation systems
[16]. It seems remarkable that the power of an individual
parameter, S1P, to predict septic shock is comparable to
that of the complex SOFA score. An explanation for this
may be that S1P inhibits multiple processes relating to
sepsis severity:













































Fig. 1 Serum-S1P is not dependent on age (a) or gender (b) in
healthy controls. Linear regression analysis with 95 % confidence
interval (a) and median with interquartile range are given and groups
were compared using Mann–Whitney U test (b). n.s. non-significant,
S1P sphingosine-1-phosphate
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(1) Endothelial barrier disruption plays a critical role in
sepsis pertaining to vascular leakage, organ failure,
and septic shock. Direct involvement of plasma-S1P
in regulating barrier function has been demonstrated
in an inflammation lung injury model in mice, where
plasma-S1P levels had been lowered by knocking out
sphingosine-kinase-1 and −2 alleles. After application
of leak-inducing agents such as histamine or platelet-
activating factor, mice with decreased plasma-S1P
show increased leakage and decreased survival [10].
Conversely, increasing plasma-S1P concentrations by
intravenous administration of S1P to lung-injured
mice or dogs decreased leakage and edema formation
[11, 23].
(2) The hyper-inflammatory phase in sepsis is
characterized by excessive release of various
cytokines [24, 25]. S1P has pro- as well as anti-
inflammatory effects [8, 26]. In mice infected with
the H1N1 influenza virus, oral or intratracheal
administration of S1PR1 agonists inhibits cytokine
release and leukocyte recruitment by pulmonary
endothelial cells [12]. This anti-inflammatory
mechanism may be diminished in sepsis patients
with low serum-S1P. An important pro-inflammatory
role for S1P in inflammation is the regulation of
lymphocyte egress from lymphatic organs into the
blood. This process depends on S1PR1, which is used
by lymphocytes to detect the S1P gradient between
tissue and blood [27]. Interestingly, decreased S1P
in patients with sepsis might contribute to the
hypo-inflammatory phase of the disease, which
is characterized by immune-paralysis with
concomitant lymphopenia and typically follows
the hyper-inflammatory phase [21]. Although
lymphocyte apoptosis has been suggested as the
main cause for lymphopenia in sepsis [28], we
cannot exclude the possibility that other
mechanisms such as altered S1P-dependent
lymphocyte egress also contribute.
(3) Low S1P levels in patients with sepsis may also
contribute to hypotension in septic shock since S1P
regulates vascular tone. Intravenous infusion of S1P
into anesthetized rats results in decreased blood
flow in mesenteric and renal arteries because of
vasoconstriction [29]. In rat mesenteric
microvessels, S1P increases vasoconstriction in
vessels that had been maximally pre-constricted with
alpha-adrenergic agonists [30]. This observation
suggests that S1P might be used in septic shock when
patients no longer respond to catecholamines.
Moreover, overexpression of sphingosine-kinase-1 in
mice has been found to increase vascular tone;
conversely, overexpression of the S1P degrading
S1P-phosphoyhdrolase reduced vascular tone [31, 32].





























Fig. 2 Serum-S1P concentrations in controls and sepsis patients. Bars indicate the median and interquartile range. Mann–Whitney U test was
used to compare controls versus the entire patient cohort (All patients), and analysis-of-variance Kruskal-Wallis test was used for comparisons
between the three patient groups (*P <0.01). n.s. non-significant, S1P sphingosine-1-phosphate, SIRS systemic inflammatory response syndrome
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Although taken together these observations encourage
the development of interventional studies to test the
possibility that elevating S1P levels may be beneficial for
patients with sepsis, it should be taken into account that
S1P effects depend on the expression pattern of S1P re-
ceptors. It is likely that activation of endothelial S1PR1
antagonizes endothelial permeability [33], but activation
of S1PR2 may have the opposite effect [34]. Moreover,
S1P may have different functions in the various stages
of sepsis [34]. Therefore, activating or blocking spe-
cific S1P receptors may be a more promising approach to
alleviate sepsis symptoms than simply increasing S1P
blood concentrations.
Regulation of serum-S1P concentrations
It is unclear exactly how serum-S1P concentrations are
regulated in healthy people, and we can only speculate
why they decrease in sepsis. As both platelets and red
blood cells store and release S1P [35–37], thrombocy-
topenia and anemia in patients with sepsis may contribute
to their low serum-S1P concentrations [38, 39]. Although
data from bone marrow transplant experiments between
wild-type and inducible sphingosine-kinase knockout
mice suggest a critical role for hematopoietic cells to de-
termine plasma-S1P levels [36], observations that anemic
or thrombocytopenic mice have normal plasma S1P levels
suggest additional sources for S1P. One strong candidate






















































Fig. 3 In patients with sepsis, serum S1P is associated with SOFA score
and mortality. a Linear regression analysis and 95 % confidence
interval with SOFA score as the dependent variable and serum-S1P
concentrations. b Mortality rate in relation to the serum-S1P
concentration and the SOFA score. Bars indicate medians and
interquartile range for S1P. *Analysis-of-variance Kruskal-Wallis test
(P <0.01). #Chi-square test (P <0.05). S1P sphingosine-1-phosphate,
SOFA Sequential Organ Failure Assessment
Table 2 Correlations between serum-S1P concentrations and
various clinical parameters






Fluid balance −0.23 <0.05
S1P sphingosine-1-phosphate, PCT procalcitonin, IL-6 interleukin-6, CRP
C-reactive protein
Correlations between S1P and PCT, IL-6, CRP, creatinine, lactate, and fluid
balance were assessed by using the Spearman rank test
Fig. 4 Receiver operating characteristic (ROC) curves for the
prediction of septic shock. PCT and IL-6 have been transformed to
log10 scale to achieve normal distribution. AUC area under the curve
(95 % confidence interval), CRP C-reactive protein, IL-6 interleukin-6,
PCT procalcitonin, S1P sphingosine-1-phosphate, SOFA Sequential
Organ Failure Assessment score
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is the endothelium, as endothelial cells produce S1P
in response to laminar flow [40]. Serum-S1P levels
may also depend on the concentration of S1P carrier
proteins. About 50 % of S1P in plasma is bound to
high-density lipoprotein HDL [41], and apolipoprotein
M (ApoM) was recently identified as the responsible
binding protein [42]. In sepsis, both HDL and ApoM
concentrations are decreased, and like S1P, they are
negatively associated with sepsis severity [43–45].
Taken together, decreased endothelial S1P produc-
tion and loss of S1P sources and carrier proteins may
all contribute to decreased S1P levels in patients with
sepsis.
Decreased serum-S1P concentrations have also
been reported in patients with dengue fever. As in
sepsis, a hallmark of this disease is the loss of endo-
thelial barrier function which is maintained by S1P/
S1PR1 signaling [20]. It is an interesting possibility
that, in these diseases, endothelial damage may cause
decreased S1P production, which in turn may further
promote endothelial damage. If so, elevating S1P
levels may break this vicious cycle and constitute a
novel approach to stabilizing patients who have vas-
cular leakage.
Limitations of our study are that it was carried out at
a single center and involved relatively small numbers of
patients with sepsis. Nevertheless, we believe that our
observations warrant follow-up studies with larger patient
groups to confirm the power of serum-S1P to predict
sepsis severity as well as studies to investigate whether
patients with sepsis might benefit from therapeutically
elevating serum-S1P levels.
Conclusion
Our observations of low concentrations of S1P in
sepsis and septic shock suggest that S1P might play a
decisive pathophysiological role in sepsis by regulating
endothelial permeability, cytokine release, and vascu-
lar tone.
Key messages
 Concentration of serum sphingosine-1-phosphate
(S1P) is decreased in patients with sepsis.
 Decreased serum-S1P concentrations are associated
with sepsis severity.
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